Muscle strength and fatigue after selective glycogen depletion in human skeletal muscle fibers

I. Jacobs,P. Kaiser,P. Tesch

DOI: https://doi.org/10.1007/BF00422176

European Journal of Applied Physiology and Occupational Physiology

Abstract:

What problem does this paper attempt to address?

Impact of point‐of‐care HIV viral load and targeted drug resistance mutation testing on viral suppression among Kenyan pregnant and postpartum women: results from a prospective cohort study (Opt4Mamas)

Rena C. Patel,Patrick Oyaro,Katherine K. Thomas,Garoma Wakjira Basha,James Wagude,Irene Mukui,Evelyn Brown,Shukri A. Hassan,Eunice Kinywa,Fredrick Oluoch,Francesca Odhiambo,Boaz Oyaro,Leonard Kingwara,Enericah Karauki,Nashon Yongo,Lindah Otieno,Grace C. John‐Stewart,Lisa L. Abuogi

DOI: https://doi.org/10.1002/jia2.26182

2023-11-10

Journal of the International AIDS Society

Abstract:Abstract Introduction Lack of viral suppression (VS) among pregnant and breastfeeding women living with HIV poses challenges for maternal and infant health, and viral load (VL) monitoring via centralized laboratory systems faces many barriers. We aimed to determine the impact of point‐of‐care (POC) VL and targeted drug resistance mutation (DRM) testing in improving VS among pregnant and postpartum women on antiretroviral therapy. Methods We conducted a pre/post‐intervention prospective cohort study among 820 pregnant women accessing HIV care at five public‐sector facilities in western Kenya from 2019 to 2022. The pre‐intervention or “control” group consisted of standard‐of‐care (SOC) centralized VL testing every 6 months and the post‐intervention or “intervention” group consisted of a combined strategy of POC VL every 3 months, targeted DRM testing, and clinical management support. The primary outcome was VS (VL ≤1000 copies/ml) at 6 months postpartum; secondary outcomes included uptake and turnaround times for VL testing and sustained VS. Results At 6 months postpartum, 321/328 (98%) of participants in the intervention group and 339/347 (98%) in the control group achieved VS (aRR 1.00, 95% confidence interval [CI] 0.98, 1.02). When assessing VS using a threshold of 1000 copies/ml) who underwent successful DRM testing in the intervention group, all (46/46, 100%) had some DRMs and 20 (43%) had major DRMs (of which 80% were nucleos(t)ide reverse transcriptase inhibitor mutations). POC VL testing uptake was high (>89%) throughout pregnancy, delivery, and postpartum periods, with a median turnaround time of 1 day (IQR 1, 4) for POC VL in the intervention group and 7 days (IQR 5, 9) for SOC VL in the control group. Sustained VS throughout follow‐up was similar between groups with either POC or SOC VL testing (90−91% for <1000 copies/ml, 62–70% for <40 copies/ml). Conclusions Our combined strategy markedly decreased turnaround time but did not increase VS rates, which were already very high, or sustained VS among pregnant and postpartum women living with HIV. Further research on how best to utilize POC VL and DRM testing is needed to optimize sustained VS among this population.

immunology,infectious diseases
Neuroendocrine differentiation of prostate cancer.

Zhen Li,Clark J. Chen,Jason K. Wang,E. Hsia,Wei Li,Jill M. Squires,Yin Sun,Jiaoti Huang

DOI: https://doi.org/10.1038/aja.2013.7

2013-05-06

Asian Journal of Andrology

Abstract:
More Frequent HIV Viral Load Testing With Point-Of-Care Tests Detects Elevated Viral Load Earlier in Postpartum HIV-Positive Women in a Randomized Controlled Trial in Two Clinics in Johannesburg, South Africa

Lee Fairlie,Shobna Sawry,Sherri Pals,Gayle Sherman,Dhelia Williamson,Jean Le Roux,Bernadette Ngeno,Leigh Berrie,Karidia Diallo,Mackenzie Hurlston Cox,Mary Mogashoa,Matthew Chersich,Surbhi Modi,OPPTIM (Optimised Postpartum PMTCT Testing for Infants and their Mothers) Study Team

DOI: https://doi.org/10.1097/QAI.0000000000003295

2023-12-15

Abstract:Background: Elevated maternal HIV viral load (VL) increases vertical transmission risk for breastfeeding children. This randomized controlled trial in Johannesburg primarily evaluated whether 3-monthly point-of-care testing, with laboratory-based standard-of-care testing (arm 2), compared with 6-monthly laboratory-based VL testing (arm 1) in postpartum women living with HIV receiving first-line tenofovir-emtricitabine-efavirenz antiretroviral treatment improved VL suppression, factors associated with nonsuppression, and drug resistance in those with virologic failure. Methods: Mother-child pairs were enrolled July 2018-April 2019 at the child's 6/10/14-week clinic visit. Women were randomized 1:1 to arm 1 or 2. Trained staff performed point-of-care VL testing using the Cepheid's Xpert HIV-1 VL assay. We fitted a generalized linear mixed model with VL suppression (<50 copies/mL (cps/mL) and <1000 cps/mL) at enrollment and 6, 12, and 18 months postpartum as the outcome and indicator variables for time, study site, study arm, and interaction variables. The final model tested for a difference by study arm, pooling across time points. Results: Of 405 women enrolled (204 arm 1 and 201 arm 2), 249 (61%) remained in follow-up through 18 months. There was no difference in VL suppression between arms at 6, 12, or 18 months. VL suppression rate (<50 cps/mL) at 18 months was 64.8% in arm 1 and 63.0% in arm 2 (P = 0.27). On bivariate analysis, there was an association with late antenatal booking and being in arm 2 for nonsuppressed VL, but no significant association with breastfeeding. HIV drug resistance was found in 12 of 23 participants (52.2%). Conclusion: We found no significant difference in VL suppression with more frequent VL testing in postpartum women living with HIV receiving first-line efavirenz-based antiretroviral treatment.
"They test my blood to know how much blood is in my body": the untapped potential of promoting viral load literacy to support adherence and viral suppression among adolescents living with HIV

Sarah Bernays,Joni Lariat,Frances Cowan,Beula Senzanje,Nicola Willis,Zivai Mupambireyi Nenguke

DOI: https://doi.org/10.1002/jia2.26153

Abstract:Introduction: Achieving sustained HIV viral suppression is a key strategy to optimize the health and wellbeing of those living with HIV. Sub-optimal adherence to antiretroviral therapy (ART) in adolescents and young people living with HIV (AYPLHIV) in Southern Africa, due to a range of social and contextual factors, including poor mental health, has presented a substantial challenge to meeting targets aimed towards improving treatment outcomes and reducing transmission. With the increasing availability of viral load (VL) testing in Southern Africa, there is an opportunity to better understand the relationship between VL literacy, wellbeing and adherence among adolescents. Methods: We conducted qualitative interviews with 45 AYPLHIV aged 10-24 years in three districts (urban, peri-urban and rural) in Zimbabwe between March and August 2021. The sample was purposively selected to represent a range of experiences related to HIV status disclosure, gender, marital status and treatment experience. Separate workshops were conducted with 18 healthcare workers (HCWs) and 20 caregivers to better understand existing support mechanisms to AYPLHIV accessing ART. We used thematic analysis to examine adolescent VL literacy, treatment support networks, experiences of clinic interactions, VL testing procedures and barriers to adherence. Results: VL literacy was consistently under-developed among participants. Comprehension of phrases commonly heard during clinic visits, such as TND (target not detected) and "high" and "low" VL, were better understood by older participants. VL testing was predominantly understood as a clinical procedure that enables HCWs to monitor treatment adherence. Absent throughout the interviews were descriptions of how viral suppression improves health and quality of life, likely fosters wellbeing and enhances self-esteem, enables participation in education and social activities, and eliminates the risk of onward transmission. Conclusions: It is imperative that we reconsider how routine VL monitoring is communicated to and understood by AYPLHIV. Reframing ART, including VL test results, in terms of the psychosocial benefits that viral suppression can generate is likely to be crucial to motivating AYPLHIV to maintain optimal treatment engagement and develop self-management approaches as they move into adulthood. Access to accurate information tailored to individual concerns and circumstances can support AYPLHIV to achieve wellbeing.
Implementation of Point of Care HIV Viral Load Monitoring for People living with HIV in Low and Middle-income Countries: A Systematic Review on Implementation Research Outcomes.

Perry Cyril Msoka,Iraseni Swai,Kennedy Ngowi,Ria Reis,Andreja Lekic,Blandina Mmbaga,Anita Hardon,Marion Sumari-de Boer

DOI: https://doi.org/10.1101/2024.11.04.24316630

2024-11-05

Abstract:Background Viral load monitoring has rapidly increased among people living with HIV(PLHIV) in low- and middle-income countries (LMICs), resulting in an increased laboratory workload. The use of innovative Point of Care (PoC) or near Point of Care (n)PoC HIV Viral Load (HIV VL) monitoring has enabled improved patient care, a reduction in laboratory workload, improved clinic retention and reduced turnaround time of results. However, implementation bottlenecks of such methods are uncertain, especially when PoC or (n)PoC is implemented in remote areas in low-volume clinics. The main aim of this study was to review implementation research outcomes of (n)PoC HIV VL monitoring for PLHIV in LMICs. Methodology We qualitatively synthesised peer-reviewed papers to explore implementation research outcomes (IROs) of (n)PoC HIV VL monitoring. We identified studies published between January 2013 and June 2024. We used the IROs described by Proctor et al., which are acceptability, adoption, appropriateness, cost, feasibility, fidelity, penetration and sustainability. We searched using the following Mesh terms: Point of care testing, HIV, viral load, acceptability, patient acceptance of health care, adoption, facilities and services utilisation, appropriateness, cost, feasibility, fidelity, penetration, coverage, sustainability and continuity of patient care through PubMed, Cochrane and Scopus. The PRISMA diagram in Figure 1 presents the selection process of included papers. Results Twenty-five studies reported implementation outcomes of PoC or (n)PoC HIV VL monitoring. Near PoC HIV VL monitoring using GeneXpert is considered acceptable to patients and healthcare providers. Point of care HIV VL monitoring using mPIMA was feasible as patients received the results the same day. From a health service provider’s perspective, PoC HIV VL monitoring was acceptable because it influenced patients to accept the illness and adhere to medication. Additionally, there was high testing coverage in routine PoC HIV VL monitoring centres. Fidelity was questionable in some settings due to (n)PoC HIV VL monitoring results not being delivered as intended. Additionally, we found in several studies that the (n)PoC costs are higher than standard of care test, USD 54.93 per test, at low testing volume clinics conducting 20VL tests per month compared to costs of USD 24.25 at high testing volume clinics conducting 100VL tests per month. However, costs are expected to be lower when (n)PoC HIV VL monitoring is scaled up and targeted for those at risk. Conclusion Implementation of PoC or (n)PoC testing for HIV viral load monitoring is acceptable and feasible and can reach a vast population. However, higher costs, limited fidelity, lower penetration and limited sustainability may hinder using (n)PoC testing in improving patient care and health outcomes. More knowledge and training should be implemented to overcome these challenges.
The potential promise and pitfalls of point-of-care viral load monitoring to expedite HIV treatment decision-making in rural Uganda: a qualitative study

Joseph G. Rosen,William G. Ddaaki,Neema Nakyanjo,Larry W. Chang,Anh Van Vo,Tongying Zhao,Gertrude Nakigozi,Fred Nalugoda,Godfrey Kigozi,Joseph Kagaayi,Thomas C. Quinn,M. Kate Grabowski,Steven J. Reynolds,Caitlin E. Kennedy,Ronald M. Galiwango

DOI: https://doi.org/10.1186/s12913-024-11747-w

2024-10-23

BMC Health Services Research

Abstract:HIV treatment programs in Africa have implemented centralized testing for routine viral load monitoring (VLM), which may result in specimen processing delays inhibiting timely return of viral load results. Decentralized, point-of-care (PoC) VLM is a promising tool for expediting HIV clinical decision-making but remains unavailable in most African settings. We qualitatively explored the perceived feasibility and appropriateness of PoC VLM to address gaps along the viral load monitoring continuum in rural Uganda.

health care sciences & services
"I feel drug resistance testing allowed us to make an informed decision": qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya

Andrea J Scallon,Shukri A Hassan,Shirley Rui Qian,Yuandi Gao,Patrick Oyaro,Evelyn Brown,James Wagude,Irene Mukui,Eunice Kinywa,Frederick Oluoch,Francesca Odhiambo,Boaz Oyaro,Leonard Kingwara,Nashon Yongo,Enericah Karauki,Lindah Otieno,Grace C John-Stewart,Lisa L Abuogi,Rena C Patel

DOI: https://doi.org/10.1186/s12913-023-09804-x

2023-08-24

Abstract:Background: Pregnant women and children living with HIV in Kenya achieve viral suppression (VS) at lower rates than other adults. While many factors contribute to these low rates, the acquisition and development of HIV drug resistance mutations (DRMs) are a contributing factor. Recognizing the significance of DRMs in treatment decisions, resource-limited settings are scaling up national DRM testing programs. From provider and patient perspectives, however, optimal ways to operationalize and scale-up DRM testing in such settings remain unclear. Methods: Our mixed methods study evaluates the attitudes towards, facilitators to, and barriers to DRM testing approaches among children and pregnant women on antiretroviral therapy (ART) in five HIV treatment facilities in Kenya. We conducted 68 key informant interviews (KIIs) from December 2019 to December 2020 with adolescents, caregivers, pregnant women newly initiating ART or with a high viral load, and providers, laboratory/facility leadership, and policy makers. Our KII guides covered the following domains: (1) DRM testing experiences in routine care and through our intervention and (2) barriers and facilitators to routine and point-of-care DRM testing scale-up. We used inductive coding and thematic analysis to identify dominant themes with convergent and divergent subthemes. Results: The following themes emerged from our analysis: (1) DRM testing and counseling were valuable to clinical decision-making and reassuring to patients, with timely results allowing providers to change patient ART regimens faster; (2) providers and policymakers desired an amended and potentially decentralized DRM testing process that incorporates quicker sample-to-results turn-around-time, less burdensome procedures, and greater patient and provider "empowerment" to increase comfort with testing protocols; (3) facility-level delays, deriving from overworked facilities and sample tracking difficulties, were highlighted as areas for improvement. Conclusions: DRM testing has the potential to considerably improve patient health outcomes. Key informants recognized several obstacles to implementation and desired a more simplified, time-efficient, and potentially decentralized DRM testing process that builds provider comfort and confidence with DRM testing protocols. Further investigating the implementation, endurance, and effectiveness of DRM testing training is critical to addressing the barriers and areas of improvement highlighted in our study. Trial registration: NCT03820323.
Impact of point-of-care birth test-and-treat on clinical outcomes among infants with HIV: A cluster randomized trial in Mozambique and Tanzania

Ilesh V Jani,Issa Sabi,Kira Elsbernd,Bindiya Meggi,Arlete Mahumane,Anange Fred Lwilla,Kassia Pereira,Siriel Boniface,Raphael Edom,Joaquim Lequechane,Falume Chale,Nhamo Chiwerengo,Nyanda E Ntinginya,Chishamiso Mudenyanga,Mariana Mueller,Martina Rauscher,Michael Hoelscher,Nuno Taveira,W Chris Buck,Arne Kroidl,the LIFE study consortium,Lise Ellyin,Araújo Patricio,Dadirai Mutsaka,Lara Samuel,Sergey Bocharnikov,Timothy Bollinger,Wilson Simbine,Abhishek Bakuli,Cornelia Lueer,Elmar Saathoff,Fidelina Zekoll,Friedrich Rieß,Otto Geisenberger,Rute Marcelino,Absalao Zumba,Daniel Machavae,Adolfo Vubil,Ana Duajá,Jacinto Adolfo Ndarissone,Joao Manuel,Maria Maviga,Nalia Ismael,Jorge Morais,Nedio Mabunda,Adolfo Vubil,Fatima Mecupa,Amina de Sousa,Abisai Kisinda,Chacha Mangu,Doreen Pamba,Festina Paschal,Hellen Mahiga,Janeth Stephen,Lilian Njovu,Magreth Haule,Oliver Lyoba,Theodora Mbunda,Willyhelmina Olomi

DOI: https://doi.org/10.1093/cid/ciae530

IF: 20.999

2024-11-10

Clinical Infectious Diseases

Abstract:We assessed the impact of point-of-care (PoC) test-and-treat at birth on clinical outcomes and viral suppression among HIV-positive infants in Mozambique and Tanzania. This cluster-randomized trial allocated health facilities to intervention, providing PoC-testing and antiretroviral treatment (ART) at birth and week 4-8, or control, starting these at week 4-8. The primary outcome was proportions of clinical events (mortality, morbidity, retention, virological failure, toxicity) among HIV-positive infants at month-18. We estimated incidence rate ratios adjusted for timing of HIV-detection (aIRR) and reported viral suppression <1000 copies/mL. Among 6602 neonates enrolled October 2019-September 2021, 125 were diagnosed HIV-positive by week 12. In the intervention arm, 38/69 (55.1%) were diagnosed at birth with 35 initiating ART within two days. In the control arm, 27/56 (48.2%) were retrospectively detected HIV-positive at birth, of whom 6/56 (10.7%) died or were lost to follow-up before testing. Median age at ART initiation was 6 (intervention) versus 33 days (control). Birth test-and-treat was not associated with a significant reduction in clinical outcomes up to month-18 [53 (76.8%) versus 48 (85.7%); aIRR 0.857; 95% CI 0.505–1.492], but showed a 68% relative reduction in 6-month mortality. Viral suppression was poor overall, but improved in the intervention group at month 18 (65.7% versus 29.6%; p=0.005). PoC test-and-treat at birth is feasible in resource-poor settings and resulted in clinically-relevant reduction of early infant mortality, though improved clinical outcomes were not sustained to month-18. Poor viral suppression may undermine early survival benefits, calling for better paediatric treatments and tailored adherence interventions. This graphical abstract is also available at Tidbit: https://tidbitapp.io/institutional-portal/clinical-infectious-diseases/tidbits/impact-of-point-of-care-birth-test-and-treat-on-clinical-outcomes-among-infants-with-hiv-a-cluster-randomized-trial-in-mozambique-and-tanzania-b24b5824-f7c1-4058-aba0-d1aaeb7c4117/update

immunology,infectious diseases,microbiology
Enhanced peer-group strategies to support the prevention of mother-to-child HIV transmission leads to increased retention in care in Uganda: A randomized controlled trial

Alexander Amone,Grace Gabagaya,Priscilla Wavamunno,Gordon Rukundo,Joyce Namale-Matovu,Samuel S. Malamba,Irene Lubega,Jaco Homsy,Rachel King,Clemensia Nakabiito,Zikulah Namukwaya,Mary Glenn Fowler,Philippa Musoke

DOI: https://doi.org/10.1371/journal.pone.0297652

IF: 3.7

2024-04-19

PLoS ONE

Abstract:Introduction Despite the scale-up of Option B+, long-term retention of women in HIV care during pregnancy and the postpartum period remains an important challenge. We compared adherence to clinic appointments and antiretroviral therapy (ART) at 6 weeks, 6, and and 24 months postpartum among pregnant women living with HIV and initiating Option B+. Women were randomized to a peer group support, community-based drug distribution and income-generating intervention called “Friends for Life Circles” (FLCs) versus the standard of care (SOC). Our secondary outcome was infant HIV status and HIV-free survival at 6 weeks and 18 months postpartum. Methods Between 16 May 2016 and 12 September 2017, 540 ART-naïve pregnant women living with HIV at urban and rural health facilities in Uganda were enrolled in the study at any gestational age. Participants were randomized 1:1 to the unblinded FLC intervention or SOC at enrolment and assessed for adherence to the prevention of mother-to-child HIV transmission (PMTCT) clinic appointments at 6 weeks, 12, and 24 months postpartum, self-reported adherence to ART at 6 weeks, 6 and 24 months postpartum and supported by plasma HIV-1 RNA viral load (VL) measured at the same time points, retention in care through the end of study, and HIV status and HIV-free survival of infants at 18 months postpartum. The FLC groups were formed during pregnancy within 4 months of enrollment and held monthly meetings in their communites, and were followed up until the last group participant reached 24 months post delivery. We used Log-rank and Chi-Square p-values to test the equality of Kaplan-Meier survival probabilities and hazard rates (HR) for failure to retain in care for any reason by study arm. Results There was no significant difference in adherence to PMTCT clinic visits or to ART or in median viral loads between FLC and SOC arms at any follow-up time points. Retention in care through the end of study was high in both arms but significantly higher among participants randomized to FLC (86.7%) compared to SOC (79.3%), p = 0.022. The adjusted HR of visit dropout was 2.4 times greater among participants randomized to SOC compared to FLC (aHR = 2.363, 95% CI: 1.199–4.656, p = 0.013). Median VL remained < 400 copies/ml in both arms at 6 weeks, 6, and 24 months postpartum. Eight of the 431 infants tested at 18 months were HIV positive (1.9%), however, this was not statistically different among mothers enrolled in the FLC arm compared to those in the SOC arm. At 18 months, HIV-free survival of children born to mothers in the FLC arm was significantly higher than that of children born to mothers in the SOC arm. Conclusions Our findings suggest that programmatic interventions that provide group support, community-based ART distribution, and income-generation activities may contribute to retention in PMTCT care, HIV-free survival of children born to women living with HIV, and ultimately, to the elimination of mother-to-child HIV transmission (EMTCT). Trial registration NCT02515370 (04/08/2015) on ClinicalTrials.gov.

multidisciplinary sciences
CHEMICAL REACTION IN THE INTERFEROMETER U-GA UGE By CARL BARus

C. Barus

Abstract:We have also been able to make satisfactory glass potential measurements in humid summer weather under conditions which would have proved hopeless for the quadrant electrometer. This may be due to the fact that the electrostatic field associated with the 2.3-volt grid circuit is so small in comparison with that present in the vicinity of the electrometer vane (50 volts) that stray atmospheric charges are not so readily collected in the former case. 1 N. H. Furman, J. Am. Chem. Soc., 44, 2685, 1922; Trans. Am. Electroch. Soc., 43, 79, 1923; Van der Meulen and Wilcoxon, J. I. E. C., 15, 62, 1923; Popoff and McHenry, J. I. E. C., 20, 534, 1928; W. T. Richards, J. Phys. Chem., 32, 990, 1928; Closs and Kahlenberg, Trans. Am. Electroch. Soc., preprint, Sept. 24, 1928. 2 E. J. Roberts and F. Fenwick, J. Am. Chem. Soc., 50, 2125, 1928. 3 W. S. Hughes, (a) J. Am. Chem. Soc., 44,2860, 1922; (b) J. Chem. Soc., 1928,491; F. J. Watson, Chem. Eng. Min. Rev., 20, 59, 1927; Kerridge, Biochem. Journal, 19, 611, 1925. 4 Jones and Kaplan, J. Am. Chem. Soc., 50, 1845, 1928; C. E. Davis and G. M. Davidson, Ibid., 50, 2053, 1928; Beans and Walden, Ibid., 50, 2673, 1928. 5 (a) Goode, J. Am. Chem. Soc., 44, 26, 1922; (b) Treadwell, Helv. Chim. Acta., 8, 89, 1925; (c) Williams and Whitenack, J. Phys. Ch., 31, 519, 1927; (d) C. Morton, Trans. Faraday Soc., 24, 14, 1928; (e) E. Linde, Svensk. Kem. Tidskrift, 39, 285, 1927. 6 After most of this work had been completed (August 12th) the authors learned that H. M. Partridge has carried out similar measurements of glass cell potentials with a vacuum tube potentiometer, at New York University. I MacInnes and Parker, J. Am. Chem. Soc., 37, 1449, 1915. 8 Willard and Fenwick, Ibid., 44, 2508, 1922.
Breast cancer found at screening and previous detection by women themselves

H. Joensuu,P. Klemi,J. Tuominen,O. Räsänen,I. Parvinen

DOI: https://doi.org/10.1016/0140-6736(92)91396-P

IF: 202.731

1992-02-01

The Lancet

Abstract:
Mechanisms of action of intrathecal medications.

R. Simpson

DOI: https://doi.org/10.1016/S1042-3680(03)00013-5

IF: 3.348

2003-07-01

Neurosurgery Clinics of North America

Abstract:
Development of hypergammaglobulinemia in tropical canine pancytopenia.

Burghen Ga,Beisel Wr,Walker Js,Nims Rm,D. Huxsoll,Hildebrandt Pk

1971-05-01

American Journal of Veterinary Research

Abstract:
Implementation of a safer conception programme for HIV-affected men and women in rural Uganda

Lynn T. Matthews,Moran Owembabazi,Deogratius Tukwasibwe,Alice Najjuma,Winnie Muyindike,John Mary Tumwine,Benjamin Hornstein,John Bassler,Dustin Long,Elizabeth Gill,Cynthia Young,Pooja Chitneni,Christina Psaros,Micheal Kanyesigye,Paul Kato Kalyebara,Angela Kaida,Mwebesa Bwana

DOI: https://doi.org/10.1080/17441692.2024.2342023

2024-05-09

Global Public Health

Abstract:We integrated safer conception care into a Ugandan HIV clinic. People with HIV (PWH), or partnered with a PWH, and desiring children were eligible for the Healthy Families Clinic Program. Clients completed quarterly safer conception counselling visits and questionnaires to provide information around method preferences and outcomes (partner pregnancy, partner seroconversion). We used clinic level data to evaluate longitudinal viral suppression among PWH. Between November 2016 and January 2020, 361 clients (53% men) accessed services. 75% were PWH (51% women, 96% men): 99% were on antiretroviral therapy (ART) and most reported HIV-sero-different partnerships (97%). Frequently selected safer conception methods included ART (86%), timed condomless sex (74%), and PrEP (40%) with important differences by HIV-serostatus and gender. 22.5% reported pregnancy. Most (97%) PWH were virally suppressed at enrolment and 81% of non-virally suppressed PWH were virally suppressed at 15 months. Two HIV-negative clients (2%) had HIV seroconversion. There is demand for safer conception care in a public sector HIV-clinic in Uganda. Men and women have unique safer conception care preferences. The majority of clients engaged in safer conception care had viral suppression at follow up.

public, environmental & occupational health
New insights into GPCR function: implications for HTS.

R. Eglen,T. Reisine

DOI: https://doi.org/10.1007/978-1-60327-317-6_1

Abstract:
Barriers and facilitators to viral load suppression among people living with HIV following intensive adherence counseling in Kampala, Uganda: A qualitative study

Jonathan Izudi,Adithya Cattamanchi,Barbara Castelnuovo,Rachel King

DOI: https://doi.org/10.1016/j.socscimed.2024.116595

IF: 5.379

2024-02-01

Social Science & Medicine

Abstract:We explored the barriers and facilitators to viral load (VL) suppression after three or more intensive adherence counseling (IAC) sessions among adolescents and adults living with human immunodeficiency virus (HIV) on a first-line anti-retroviral therapy (ART) with initially unsuppressed VL in Kampala, Uganda. Using a qualitative study, data were collected through in-depth interviews with people living with HIV (PLHIV) with unsuppressed and suppressed VL and caregivers of younger adolescents living with HIV after three or more IAC sessions. We held key informant interviews with health workers involved in IAC implementation, namely ART/HIV focal persons, IAC Team Leaders, and linkage facilitators. Guided by the socioecological model, we performed content analysis and reported the findings using themes along with the participants' quotes. We studied 24 participants and found the individual-level barriers as forgetting to take HIV medications, high pill burden, medication side effects, a lack of food, and HIV-related psychological distress. Undisclosed HIV status and broken families were the barriers at the interpersonal level. Institutional-level barriers included insufficient HIV and ART counseling. Stigma was considered a community-level barrier while nonadherence to HIV treatment guidelines was a policy-level barrier. Facilitators included personal reminders, knowing the importance of taking treatment, and the ability to deal with side effects of HIV medications at the personal level; treatment support, peer support clubs, and incentivized treatment at the interpersonal level; and mental health support club and explaining during counseling that HIV is a chronic disease at the institutional level. We found an unsuppressed VL after completing IAC was due to several barriers at the personal, interpersonal, health systems, community, and policy levels. Achieving ≥95% VL suppression necessitates tackling the barriers to VL suppression and scaling up the facilitators by HIV control programs.

public, environmental & occupational health,social sciences, biomedical
The impact of Option B+ policy on engagement in HIV care and viral suppression among pregnant women living with HIV in South Africa

Cornelius Nattey,Mhairi Maskew,Nelly Jinga,Amy Wise,Nicola van Dongen,Thalia Ferreira Brizido,Maanda Mudau,Karl-Günter Technau,Kate Clouse

DOI: https://doi.org/10.1101/2024.11.08.24316965

2024-11-08

Abstract:Background: Early access to HIV care impacts maternal outcomes and the risk of vertical transmission of HIV Option B+, a policy that mandates offering all pregnant women living with HIV (PWLH) lifelong antiretroviral therapy (ART) irrespective of their CD4 count, has been adopted across sub-Saharan Africa, including South Africa since 2015. This study aimed to assess the impact of Option B+ on engagement in HIV care and viral suppression among pregnant women in South Africa. Methods: This observational study used data from pregnant women living with HIV who delivered at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa from 2013-2017. Linkage to a national HIV laboratory cohort (the NHLS National HIV cohort) was used to ascertain engagement in HIV care prior to antenatal care (ANC) entry and viral load outcomes. Analyses were stratified by the pre-Option B+ (2013-2015) and Option B+ (2016-2017) eras. We compared engagement rates before and during the Option B+ era and assessed factors associated with HIV care engagement and viral suppression. Risk ratios were estimated using log-binomial regression. Results: Among 4,865 PWLH, 65% had evidence of prior engagement in HIV care. Prior engagement in care was higher during the Option B+ era (66%) compared to the pre-Option B+ era (55%) (p<0.001). Younger women (18-24 years) were less likely to engage in HIV care than those aged 25-34 years (aRR 0.8, 95% CI: 0.6-0.9). Women with CD4 counts <200 cells/mm³ were less likely to have been engaged in care prior to pregnancy compared to those with CD4 ≥500 (aRR 0.6, 95% CI: 0.6-0.7). Primigravid women had a 30% lower likelihood of earlier HIV care engagement compared to those with 2-3 pregnancies (aRR 0.7, 95% CI: 0.5-0.8). Overall viral suppression was higher in women reporting prior ART use compared to those with no prior HIV care (33% vs. 19%, p<0.001). During the four-year study period, the proportion of PWLH who had a viral load recorded but were not virally suppressed ranged from 22-36%. Conclusion: The Option B+ policy led to increased engagement in HIV care prior to pregnancy. However, high prevalence of unsuppressed viral load during the Option B+ era highlights the need for continued monitoring and support to sustain the benefits of this policy. Pregnancy and antenatal care services remain an essential portal of entry to HIV care among PWLH in South Africa. Interventions to improve early ANC attendance and maternal engagement in HIV care prior to pregnancy are critical to eliminate vertical HIV transmission.

Public and Global Health
Temporal dynamics and drivers of durable HIV viral load suppression and persistent high‐ and low‐level viraemia during Universal Test and Treat scale‐up in Uganda: a population‐based study

Joseph Gregory Rosen,Robert Ssekubugu,Larry W. Chang,Victor Ssempijja,Ronald M. Galiwango,Joseph Ssekasanvu,Anthony Ndyanabo,Alice Kisakye,Gertrude Nakigozi,Katherine B. Rucinski,Eshan U. Patel,Caitlin E. Kennedy,Fred Nalugoda,Godfrey Kigozi,Oliver Ratmann,Lisa J. Nelson,Lisa A. Mills,Donna Kabatesi,Aaron A. R. Tobian,Thomas C. Quinn,Joseph Kagaayi,Steven J. Reynolds,Mary Kathryn Grabowski

DOI: https://doi.org/10.1002/jia2.26200

2024-02-01

Journal of the International AIDS Society

Abstract:Abstract Introduction Population‐level data on durable HIV viral load suppression (VLS) following the implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viraemia among persons living with HIV in 40 Ugandan communities during the UTT scale‐up. Methods In 2015–2020, we measured VLS (<200 RNA copies/ml) among participants in the Rakai Community Cohort Study, a longitudinal population‐based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low‐level (200–999 copies/ml) or high‐level (≥1000 copies/ml) viraemia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e. visit‐pairs; ∼18‐month visit intervals) and classified as durable VLS (<200 copies/ml at both visits), new/renewed VLS (<200 copies/ml at follow‐up only), viral rebound (<200 copies/ml at initial visit only) or persistent viraemia (≥200 copies/ml at both visits). Population prevalence of each outcome was assessed over calendar time. Community‐level prevalence and individual‐level predictors of persistent high‐level viraemia were also assessed using multivariable Poisson regression with generalized estimating equations. Results Overall, 3080 participants contributed 4604 visit‐pairs over three survey rounds. Most visit‐pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with any viraemia at the initial visit (23.5%, n = 1083), 46.9% remained viraemic through follow‐up, 91.3% of which was high‐level viraemia. One‐fifth (20.8%) of visit‐pairs exhibiting persistent high‐level viraemia self‐reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high‐level viraemia varied substantially across communities and was significantly elevated among young persons aged 15–29 years (vs. 40‐ to 49‐year‐olds; adjusted risk ratio [adjRR] = 2.96; 95% confidence interval [95% CI]: 2.21–3.96), males (vs. females; adjRR = 2.40, 95% CI: 1.87–3.07), persons reporting inconsistent condom use with non‐marital/casual partners (vs. persons with marital/permanent partners only; adjRR = 1.38, 95% CI: 1.10–1.74) and persons reporting hazardous alcohol use (adjRR = 1.09, 95% CI: 1.03–1.16). The prevalence of persistent high‐level viraemia was highest among males <30 years (32.0%). Conclusions Following universal ART provision, most persons living with HIV in south‐central Uganda are durably suppressed. Among persons exhibiting any viraemia, nearly half exhibited high‐level viraemia for ≥12 months and reported higher‐risk behaviours associated with onward HIV transmission. Intensified efforts linking individuals to HIV treatment services could accelerate momentum towards HIV epidemic control.

immunology,infectious diseases
Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe

Alinda M. Young,Marie C.D. Stoner,Florence Mathebula,Rebone Mohuba,Alejandro Baez,Linly Seyama,Prisca Mutero,Juliane Etima,Zayithwa Fabiano,Lee Fairlie,Ashley J. Mayo,Jennifer E. Balkus,Mei Song,Katherine Bunge,Jeanna Piper,Ivan C. Balan,Ariane van der Straten,Elizabeth T. Montgomery

DOI: https://doi.org/10.1007/s10461-024-04421-z

2024-07-26

AIDS and Behavior

Abstract:Pregnant and lactating persons in sub-Saharan Africa face a heightened risk of HIV acquisition, due to biological and behavioral factors, combined with limited access to prevention and treatment services. Oral pre-exposure prophylaxis (PrEP) and the dapivirine vaginal ring are promising tools for HIV prevention, and the ring's recent approval in multiple African countries represents a significant advancement in expanding access to HIV prevention. In a nested qualitative study within the MTN-042 trial, we explored the acceptability of study products among pregnant persons in the second and early third trimesters. Interviews were conducted privately, using a semi-structured guide with 77 participants, in participants' preferred language. Topics explored included product acceptability (using the theoretical framework of acceptability), user experience, satisfaction, disclosure, community attitudes, and sexual activity during pregnancy. Interview transcripts were analyzed using Dedoose software. We observed positive attitudes among participants towards the study products, which they found generally user-friendly, despite the added complexities of using them during pregnancy. Participants recognized that consistent and correct use would provide protection for both them and their unborn children. Although initial concerns existed, most of these worries dissipated over time, with study staff support and increased product use experience. These findings emphasize the importance of continued surveillance, support, and education to ensure the successful rollout of new HIV prevention measures during pregnancy.

public, environmental & occupational health,social sciences, biomedical
Viral load assay performs comparably to early infant diagnosis assay to diagnose infants with HIV in Mozambique: a prospective observational study

Adolfo Vubil,Carina Nhachigule,Osvaldo Loquiha,Bindiya Meggi,Nedio Mabunda,Timothy Bollinger,Jilian A Sacks,Ilesh Jani,Lara Vojnov

DOI: https://doi.org/10.1002/jia2.25422

Abstract:Introduction: Viral load testing is essential to manage HIV disease, especially in infants and children. Early infant diagnosis is performed using nucleic-acid testing in children under 18 months. Resource-limited health systems face severe challenges to scale-up both viral load and early infant diagnosis to unprecedented levels. Streamlining laboratory systems would be beneficial to improve access to quality testing and to increase efficiency of antiretroviral treatment programmes. We evaluated the performance of viral load testing to serve as an early infant diagnosis assay in children younger than 18 months. Methods: This study was an observational, prospective study, including children between one and 18 months of age who were born to HIV-positive mothers in 134 health facilities in Maputo City and Maputo Province, Mozambique. Dried blood spot specimens from heel or toe pricks were collected between January and April 2018, processed using SPEX buffer for both assays, and tested for routine EID and VL testing using the Roche CAP/CTM HIV-1 Qualitative v2 and Roche CAP/CTM HIV-1 Quantitative v2 assays respectively. The sensitivity, specificity and positive and negative predictive values were estimated using the EID results as the reference standard. Results: A total of 1021 infants were included in the study, of which 47% were female. Over 95% of mothers and children were on antiretroviral treatment or received antiretroviral prophylaxis respectively. The sensitivity and specificity of using the viral load assay to detect infection were 100% (95% CI: 96.2 to 100%) and 99.9% (95% CI: 99.4 to 100%). The positive and negative predictive values were 99.0% (95% CI: 94.3 to 100%) and 100% (95% CI: 99.6 to 100%). The McNemar's test was 1.000 and Cohen's kappa was 0.994. Conclusions: The comparable performance suggests that viral load assays can be used as an infant diagnostic assay. Infants with either low levels of viraemia or high cycle threshold values should be repeat tested to ensure the result is truly positive prior to treatment initiation, regardless of assay used. Viral load assays could replace traditional early infant diagnosis testing, substantially streamlining molecular laboratory services for children and lowering costs, with the additional advantage of providing baseline viral load results for antiretroviral treatment management.

Muscle strength and fatigue after selective glycogen depletion in human skeletal muscle fibers

Impact of point‐of‐care HIV viral load and targeted drug resistance mutation testing on viral suppression among Kenyan pregnant and postpartum women: results from a prospective cohort study (Opt4Mamas)

Neuroendocrine differentiation of prostate cancer.

More Frequent HIV Viral Load Testing With Point-Of-Care Tests Detects Elevated Viral Load Earlier in Postpartum HIV-Positive Women in a Randomized Controlled Trial in Two Clinics in Johannesburg, South Africa

"They test my blood to know how much blood is in my body": the untapped potential of promoting viral load literacy to support adherence and viral suppression among adolescents living with HIV

Implementation of Point of Care HIV Viral Load Monitoring for People living with HIV in Low and Middle-income Countries: A Systematic Review on Implementation Research Outcomes.

The potential promise and pitfalls of point-of-care viral load monitoring to expedite HIV treatment decision-making in rural Uganda: a qualitative study

"I feel drug resistance testing allowed us to make an informed decision": qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya

Impact of point-of-care birth test-and-treat on clinical outcomes among infants with HIV: A cluster randomized trial in Mozambique and Tanzania

Enhanced peer-group strategies to support the prevention of mother-to-child HIV transmission leads to increased retention in care in Uganda: A randomized controlled trial

CHEMICAL REACTION IN THE INTERFEROMETER U-GA UGE By CARL BARus

Breast cancer found at screening and previous detection by women themselves

Mechanisms of action of intrathecal medications.

Development of hypergammaglobulinemia in tropical canine pancytopenia.

Implementation of a safer conception programme for HIV-affected men and women in rural Uganda

New insights into GPCR function: implications for HTS.

Barriers and facilitators to viral load suppression among people living with HIV following intensive adherence counseling in Kampala, Uganda: A qualitative study

The impact of Option B+ policy on engagement in HIV care and viral suppression among pregnant women living with HIV in South Africa

Temporal dynamics and drivers of durable HIV viral load suppression and persistent high‐ and low‐level viraemia during Universal Test and Treat scale‐up in Uganda: a population‐based study

Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe

Viral load assay performs comparably to early infant diagnosis assay to diagnose infants with HIV in Mozambique: a prospective observational study